



VGX Pharmaceuticals announces the discontinuation of VGX-410C development and the concentration of its efforts on HIV and other product pipelines

Blue Bell, PA – December 13, 2007 –

VGX Pharmaceuticals announced today that it has completed the multi-site, multi-dose, and double-blind Phase II study for assessing the safety and antiviral effects of VGX-410C, its lead product candidate for treating HCV infection. The data showed that VGX-410C did not meet the efficacy endpoint of the study.

Although, VGX-410C was safe and well tolerated in patients in all three daily doses--150, 300, and 600 mg, one out of six patients in the 600 mg dose group had HCV viral load reduction of ten times or more (one log reduction).

Based on the study data and other on-going product development opportunities for VGX, the Company has decided to suspend any further development of VGX-410C for HCV infection and concentrate its resources for a further development of more promising drug and vaccine candidates for infectious disease, including HIV and cancer.

“VGX Pharmaceuticals has several product candidates in the pipeline with significant market potentials,” said Dr. J. Joseph Kim, CEO and President. “We will focus our resources on those programs that can create the greatest value for our Company and our shareholders.”

Most advanced programs include novel therapies and vaccines for HIV infection: PICTOVIR™ in Phase II clinical trials and PENNVAX-B™, a DNA vaccine, in Phase I clinical trials. PICTOVIR™ was filed with the FDA for a combination therapy as a part of its Phase II clinical trials, which is planned to be completed in 2008.

In addition, VGX has recently filed an Investigational New Drug Application (IND) with the FDA for VGX-1027, the Company’s lead compound for the treatment of rheumatoid arthritis and type 1 diabetes (co-developed with VGX International).

VGX Pharmaceuticals also seeks to further expand its potent DNA vaccine and delivery platform in 2008. The Company plans to file three separate INDs for promising DNA vaccine candidates during the first two quarters of 2008: VGX-3100--a therapeutic vaccine for human papilloma virus (HPV) as a treatment for cervical cancer, VGX-3200--a therapeutic based on human growth hormone releasing hormone (GHRH) for cancer-related cachexia (wasting or heavy weight loss), and VGX-3400—a pandemic avian flu vaccine. All of these vaccines are delivered by its patented CELLECTRA™ electroporation device, which just successfully completed its first tolerability studies in human volunteers.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com